• A
  • |
  • A
  • Text size

Names Under Consideration

USAN Council's statement on the use of USAN as domain names:

A name published by the United States Adopted Names (USAN) Program in the USP Dictionary of USAN and International Nonproprietary Names, and on the United States Adopted Names Web site, shall be the effective equivalent of an intellectual property right on the part of the relevant entities.

Comments or protests should be addressed to Stephanie Shubat, USAN Program Director, American Medical Association, 515 North State Street, Chicago, Illinois 60654, or sent via email to USAN@ama-assn.org.

The following list of names for the drugs described are "under consideration" by the USAN Council:

April 2013

briciclib anti-cancer agent
edabrutinib hematological malignancies and autoimmune diseases
fosabenticorat rheumatoid arthritis and potentially other inflammation diseases
pralmotinib treatment of mesothelioma and ovarian tumors
ramabecestat treatment of Alzheimer's disease
spebrutinib hematological malignancies and autoimmune diseases

March 2013

laziofolastat I 131 diagnostic agent, prostate cancer
muparfostat antineoplastic

February 2013

beclabuvir treatment of hepatitis C
cabtegravir treatment of HIV Infection
ipalisib antidepressant
latiglutenase treatment of celiac disease
venetoclax antineoplastic